Article
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
The Lancet. Oncology - 1 Aug 2015
Soria Jean-Charles, Wu Yi-Long, Nakagawa Kazuhiko, Kim Sang-We, Yang Jin-Ji, Ahn Myung-Ju, Wang Jie, Yang James Chih-Hsin, Lu You, Atagi Shinji, Ponce Santiago, Lee Dae Ho, Liu Yunpeng, Yoh Kiyotaka, Zhou Jian-Ying, Shi Xiaojin, Webster Alan, Jiang Haiyi, Mok Tony S K
Abstract excerpt
BACKGROUND: Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib. METHODS: The...
Topics
- Administration, Oral
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Asia
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Cisplatin